Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial

Reuters

2025/10/24

Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial

Sagimet Biosciences Inc. announced that data from a Phase 3 clinical trial evaluating denifanstat, an oral fatty acid synthase (FASN) inhibitor, for the treatment of moderate to severe acne vulgaris in China will be presented at the 2025 Fall Clinical Dermatology Conference, scheduled for October 24-26, 2025, in Las Vegas, Nevada. The trial, conducted by license partner Ascletis Bioscience Co. Ltd., was a randomized, double-blind, placebo-controlled, multicenter study involving 480 patients. Denifanstat met all primary and secondary endpoints, demonstrating statistically significant improvements in treatment success rates and lesion counts compared to placebo. The drug was generally well tolerated. Ascletis has completed a pre-New Drug Application (NDA) consultation with China's National Medical Products Administration and plans to submit an NDA for denifanstat in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551486-en) on October 24, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577590843"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577590843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577590843?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-24 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577590843","market":"nz","top_or_hot":-1,"title":"Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> announced that data from a Phase 3 clinical trial evaluating denifanstat, an oral fatty acid synthase (FASN) inhibitor, for the treatment of moderate to severe acne vulgaris in China will be presented at the 2025 Fall Clinical Dermatology Conference, scheduled for October 24-26, 2025, in Las Vegas, Nevada. The trial, conducted by license partner Ascletis Bioscience Co. Ltd., was a randomized, double-blind, placebo-controlled, multicenter study involving 480 patients. Denifanstat met all primary and secondary endpoints, demonstrating statistically significant improvements in treatment success rates and lesion counts compared to placebo. The drug was generally well tolerated. Ascletis has completed a pre-New Drug Application (NDA) consultation with China's National Medical Products Administration and plans to submit an NDA for denifanstat in China.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551486-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-24 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> announced that data from a Phase 3 clinical trial evaluating denifanstat, an oral fatty acid synthase (FASN) inhibitor, for the treatment of moderate to severe acne vulgaris in China will be presented at the 2025 Fall Clinical Dermatology Conference, scheduled for October 24-26, 2025, in Las Vegas, Nevada. The trial, conducted by license partner Ascletis Bioscience Co. Ltd., was a randomized, double-blind, placebo-controlled, multicenter study involving 480 patients. Denifanstat met all primary and secondary endpoints, demonstrating statistically significant improvements in treatment success rates and lesion counts compared to placebo. The drug was generally well tolerated. Ascletis has completed a pre-New Drug Application (NDA) consultation with China's National Medical Products Administration and plans to submit an NDA for denifanstat in China.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551486-en) on October 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLbn3Q5B:1","article_id":"2577590843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577590843","pubTimestamp":1761303622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sagimet Biosciences Inc. announced that data from a Phase 3 clinical trial evaluating denifanstat, an oral fatty acid synthase  inhibitor, for the treatment of moderate to severe acne vulgaris in China will be presented at the 2025 Fall Clinical Dermatology Conference, scheduled for October 24-26, 2025, in Las Vegas, Nevada. The trial, conducted by license partner Ascletis Bioscience Co. Ltd., was a randomized, double-blind, placebo-controlled, multicenter study involving 480 patients. Denifanstat met all primary and secondary endpoints, demonstrating statistically significant improvements in treatment success rates and lesion counts compared to placebo. The drug was generally well tolerated. Ascletis has completed a pre-New Drug Application  consultation with China's National Medical Products Administration and plans to submit an NDA for denifanstat in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","01672":"歌礼制药-B","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK1574":"生物医药B类股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SGMT":"Sagimet Biosciences Inc.","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK1161":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK1515":"抗疫概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Sagimet Biosciences报告Denifanstat达到3期痤疮试验的所有终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"01672":0.9,"SGMT":0.9},"content_text":"Sagimet Biosciences Reports Denifanstat Meets All Endpoints in Phase 3 Acne Trial\n    \n\nSagimet Biosciences Inc. announced that data from a Phase 3 clinical trial evaluating denifanstat, an oral fatty acid synthase (FASN) inhibitor, for the treatment of moderate to severe acne vulgaris in China will be presented at the 2025 Fall Clinical Dermatology Conference, scheduled for October 24-26, 2025, in Las Vegas, Nevada. The trial, conducted by license partner Ascletis Bioscience Co. Ltd., was a randomized, double-blind, placebo-controlled, multicenter study involving 480 patients. Denifanstat met all primary and secondary endpoints, demonstrating statistically significant improvements in treatment success rates and lesion counts compared to placebo. The drug was generally well tolerated. Ascletis has completed a pre-New Drug Application (NDA) consultation with China's National Medical Products Administration and plans to submit an NDA for denifanstat in China.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9551486-en) on October 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}